“CBOs can play an important role as local resources for sickle cell disease patients and caregivers as they navigate their healthcare journey.
Established in 2021, The GBT Foundation is a community-focused, charitable entity that is committed to improving health equity worldwide, particularly for people living with SCD. The 2022 ACE Grant recipients are:
- Advancing Sickle Cell Advocacy Project, Inc. (
Miami, Florida ) – Project COPE to help children and families navigate their SCD journey by providing peer support, education, mindfulness training, and effective stress-coping techniques. - Children’s
Sickle Cell Foundation, Inc. (Pittsburgh, Pennsylvania ) – Living Well with Sickle Cell Family Leadership Program to educate sickle cell family leaders about SCD, care, treatment, and their role in advocacy. Maryland Sickle Cell Disease Association (Baltimore, Maryland ) – Effective Access to Adult Sickle Cell Experts (EAASE) project to facilitate the hiring of a Transition Navigator to create a personal and curated experience for pediatric patients to transition to adult healthcare providers.Sickle Cell Association of South Louisiana (Lafayette , Louisiana) – KNEAUX Sickle Program to support resources for teens transitioning from pediatric to adult SCD healthcare providers.Sickle Cell Warriors, Inc. (San Diego, California ) – Sickle Cell Warriors Advocacy Training & Empowerment Program (WATEP) to educate warriors and caregivers to advocate for themselves and others living with SCD by expanding healthcare literacy.
ACE Grant Program recipients were selected by a panel of external and internal experts. Criteria for selection included the programs’ potential impact on SCD patient care, evaluation and sustainability plans, organizational capabilities, and alignment with mission of
The ACE Grant Program builds on the Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program, which is in its fourth year and is accepting applications through
About Sickle Cell Disease
It is estimated that more than 100,000 people in the
About The GBT Foundation
Founded in 2021, The GBT Foundation is a 501(c)(3) nonprofit organization, primarily funded by Global Blood Therapeutics, Inc. (GBT). Building on GBT’s corporate giving commitment, The GBT Foundation is a community-focused, charitable entity that is committed to improving health equity worldwide, particularly for people living with SCD. The GBT Foundation is a separate legal entity from GBT. To learn more, please visit www.gbt.com/gbtfoundation.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program to address significant patient needs in SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
References
Centers for Disease Control and Prevention . Sickle Cell Disease Data and Statistics (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. AccessedJune 7, 2022 .European Medicines Agency . https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125. Accessed June 12, 2020.- Ministério da Saúde (Brasil), Protocolo Clínico e Diretrizes Terapêuticas da Doença Falciforme,
Feb. 19, 2018 - National Heart, Lung, and Blood Institute. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed February 23, 2022
- Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
- Rees DC, et al.
Lancet . 2010;376(9757):2018-2031. - Kato GJ, et al. J Clin Invest. 2017;127(3):750-760.
- Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
- Nader E, et al. Front Immunol. 2020 Mar 13;11:454.
- Kanter J, et al. Blood Rev. 2013 Nov;27(6):279-87.
Contact:
+1 650-410-3258
simmergut@gbt.com
Source:
2022 GlobeNewswire, Inc., source